The failure of Merck KGAA/Pfizer Inc.'s immuno-oncology latecomer Bavencio (avelumab) to significantly improve overall survival in a Phase III third-line gastric cancer study is a blow, but it may not be as bad as it appears, because the market is small and the trial design was more rigorous than competitors' efforts.
[Sidebar#SC099853]






